AT210152T - Somatostatinpeptide - Google Patents

Somatostatinpeptide

Info

Publication number
AT210152T
AT210152T AT96924811T AT96924811T AT210152T AT 210152 T AT210152 T AT 210152T AT 96924811 T AT96924811 T AT 96924811T AT 96924811 T AT96924811 T AT 96924811T AT 210152 T AT210152 T AT 210152T
Authority
AT
Austria
Prior art keywords
somatostatinpeptide
Prior art date
Application number
AT96924811T
Other languages
German (de)
Inventor
Rainer Albert
Wilfried Bauer
Christian Bruns
Nagarajan Chandramouli
Ian Lewis
Gisbert Weckbecker
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to GBGB9513224.7A priority Critical patent/GB9513224D0/en
Priority to GBGB9600429.6A priority patent/GB9600429D0/en
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Priority to PCT/EP1996/002840 priority patent/WO1997001579A2/en
Publication of AT210152T publication Critical patent/AT210152T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT210152(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT96924811T 1995-06-29 1996-06-28 Somatostatinpeptide AT210152T (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9513224.7A GB9513224D0 (en) 1995-06-29 1995-06-29 Organic compounds
GBGB9600429.6A GB9600429D0 (en) 1996-01-10 1996-01-10 Organic compounds
PCT/EP1996/002840 WO1997001579A2 (en) 1995-06-29 1996-06-28 Somatostatin peptides

Publications (1)

Publication Number Publication Date
AT210152T true AT210152T (en) 2001-12-15

Family

ID=26307298

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96924811T AT210152T (en) 1995-06-29 1996-06-28 Somatostatinpeptide

Country Status (24)

Country Link
US (1) US6225284B1 (en)
EP (1) EP0835263B9 (en)
JP (2) JP3445796B2 (en)
KR (1) KR100454664B1 (en)
CN (1) CN1156492C (en)
AT (1) AT210152T (en)
AU (1) AU714447B2 (en)
BR (1) BR9609335B8 (en)
CA (1) CA2222524C (en)
CZ (1) CZ297381B6 (en)
DE (1) DE69617687T2 (en)
DK (1) DK0835263T3 (en)
ES (1) ES2169251T3 (en)
HU (1) HU228984B1 (en)
IL (1) IL122243A (en)
MY (1) MY147327A (en)
NO (1) NO317867B1 (en)
NZ (1) NZ313147A (en)
PL (1) PL184947B1 (en)
PT (1) PT835263E (en)
SK (1) SK284087B6 (en)
TR (1) TR199701718T1 (en)
TW (1) TW491854B (en)
WO (1) WO1997001579A2 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
JPH10251296A (en) * 1997-03-06 1998-09-22 American Cyanamid Co Peptide useful as somatostatin antagonist
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
EP0981363B1 (en) 1997-05-13 2003-07-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Somatostatin agonists for decreasing body weight
AU8019798A (en) 1997-05-13 1998-12-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Method and compositions for treating hyperlipidemia and other conditions
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
SE9802080D0 (en) * 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and / or irritable bowel syndrome and new use of substances therein
US7122172B1 (en) 2000-03-08 2006-10-17 Gerhart Graupner Methods and compositions for targeted drug delivery
US7906103B2 (en) * 2000-03-08 2011-03-15 Gerhard Graupner Methods and compositions for targeted drug delivery
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
EP1233776A4 (en) * 1999-11-29 2003-05-07 Smithkline Beecham Corp Urotensin-ii cyclic analogs
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
KR100620435B1 (en) 2001-06-08 2006-09-12 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Somatostatin-dopamine chimeric analogs
AU2002359359A1 (en) * 2001-12-28 2003-07-24 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
JP2005524657A (en) * 2002-02-27 2005-08-18 ファーメイン， エルティーディー．Ｐｈａｒｍａｉｎ，Ｌｔｄ． Compositions for delivering therapeutic agents and other substances, and methods of making and using said compositions
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
EP1358890A1 (en) 2002-05-03 2003-11-05 BioSynthema, Inc Benzothienyl analogue of somatostatine, selective for certain somatostatin receptors
EP1506000B9 (en) 2002-05-20 2011-08-31 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Squibb Bristol Myers Co Hepatitis c virus inhibitors
DE60336550D1 (en) * 2002-05-20 2011-05-12 Bristol Myers Squibb Co INHIBITORS OF HEPATITIS C VIRUS
JP4271148B2 (en) 2002-05-20 2009-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Substituted cycloalkyl P1 'hepatitis C virus inhibitors
EP1594521A4 (en) * 2002-11-25 2008-01-09 Attenuon Llc Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
WO2004052817A1 (en) 2002-12-12 2004-06-24 Novartis Ag Process for peptide synthesis of peptides containing a 4-hydroxy-proline substructure
GB0229020D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic compounds
GB0300095D0 (en) * 2003-01-03 2003-02-05 Novartis Ag Organic compounds
WO2004093807A2 (en) 2003-04-22 2004-11-04 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatin vectors
PE20050285A1 (en) * 2003-06-24 2005-06-09 Novartis Ag Pharmaceutical composition comprising cyclic analogues of somatostatin
EP1673385B1 (en) 2003-09-22 2011-03-02 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
EP1522311A1 (en) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of somatostatin or analogs thereof for the preparation of a medicament for the regulation of ovarian follicles reserve by non menopausaled women
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
DE602005025855D1 (en) 2004-01-21 2011-02-24 Boehringer Ingelheim Pharma MACROCYCLIC PEPTIDES WITH EFFECT TO THE HEPATITIS C VIRUS
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP1717247A1 (en) * 2005-04-28 2006-11-02 Schering AG Cyclic peptides binding to the somatostatin receptor
WO2006114324A1 (en) * 2005-04-28 2006-11-02 Schering Ag Compounds comprising cyclized somatostatin receptor binding peptides
EP1941902A1 (en) * 2007-01-02 2008-07-09 Novartis AG Use of Somatostatin analogs in cluster headache
US8513186B2 (en) 2007-06-29 2013-08-20 Gilead Sciences, Inc. Antiviral compounds
EA019749B1 (en) * 2007-06-29 2014-06-30 Джилид Сайэнс, Инк. Antiviral compounds
AU2008329826B2 (en) 2007-11-28 2013-01-17 Novartis Ag Use of somatostatin analogs in meningioma
SI2225271T1 (en) * 2007-12-03 2013-10-30 Italfarmaco S.P.A. New non-selective somatostatin analogues
EP2067786A1 (en) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Novel non selective analogs of somatostatin
CN102083451A (en) 2008-06-12 2011-06-01 赛恩泰新公司 Suppression of cancers
AU2009259033B2 (en) 2008-06-12 2013-11-07 Ipsen Bioinnovation Limited Suppression of neuroendocrine diseases
PL2310042T3 (en) 2008-07-08 2013-05-31 Novartis Ag Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia
EP2168983A1 (en) 2008-09-30 2010-03-31 Ipsen Pharma New octapeptide compounds and their therapeutic use
EP2172189A1 (en) 2008-10-01 2010-04-07 Novartis AG Pharmaceutical Compositions
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
MX2011006631A (en) * 2008-12-19 2011-09-06 Gilead Sciences Inc Hcv ns3 protease inhibitors.
EP2213307A1 (en) 2009-02-03 2010-08-04 Novartis AG Injectable depot formulations
EP2380596A1 (en) * 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
WO2016097962A1 (en) 2014-12-19 2016-06-23 Auro Peptides Ltd A process for the preparation of pasireotide
CN106432429A (en) * 2016-10-24 2017-02-22 合肥国肽生物科技有限公司 Synthesis method of pasireotide
EP3568205A1 (en) 2017-01-12 2019-11-20 Radiomedix Inc. Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863008A (en) * 1973-06-11 1975-01-28 American Home Prod Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en) 1979-10-31 1984-10-19 Merck & Co Inc Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en) * 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4505897A (en) * 1983-04-18 1985-03-19 The Administrators Of The Tulane Educational Fund Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en) 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
CA2012115C (en) * 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
JP2882679B2 (en) * 1989-04-26 1999-04-12 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド Linear somatostatin analog
DE69434832D1 (en) * 1993-06-23 2006-10-05 Diatide Inc Radiolabeled peptide derivatives of somatostatin for imaging and therapeutic use
US5716596A (en) * 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses

Also Published As

Publication number Publication date
DK835263T3 (en)
EP0835263B9 (en) 2002-07-24
CN1189166A (en) 1998-07-29
WO1997001579A3 (en) 1997-02-27
CA2222524C (en) 2010-01-26
KR100454664B1 (en) 2005-09-12
WO1997001579A2 (en) 1997-01-16
CA2222524A1 (en) 1997-01-16
CZ297381B6 (en) 2006-11-15
PT835263E (en) 2002-04-29
IL122243D0 (en) 1998-04-05
IL122243A (en) 2005-09-25
CZ419697A3 (en) 1998-05-13
TR199701718T1 (en) 1998-05-21
JP2003104998A (en) 2003-04-09
HU9901455A2 (en) 1999-09-28
EP0835263A2 (en) 1998-04-15
EP0835263B1 (en) 2001-12-05
NO317867B1 (en) 2004-12-27
NZ313147A (en) 1999-11-29
BR9609335B8 (en) 2014-10-07
BR9609335A (en) 1999-05-25
TW491854B (en) 2002-06-21
DK0835263T3 (en) 2002-04-02
PL184947B1 (en) 2003-01-31
AU714447B2 (en) 2000-01-06
ES2169251T3 (en) 2002-07-01
KR19990028480A (en) 1999-04-15
SK177097A3 (en) 1998-08-05
JPH11506108A (en) 1999-06-02
MY147327A (en) 2012-11-30
BR9609335B1 (en) 2009-08-11
HU9901455A3 (en) 2000-11-28
PL323943A1 (en) 1998-04-27
HU228984B1 (en) 2013-07-29
NO976064D0 (en) 1997-12-23
DE69617687D1 (en) 2002-01-17
DE69617687T2 (en) 2002-08-22
NO976064L (en) 1998-02-16
JP3445796B2 (en) 2003-09-08
SK284087B6 (en) 2004-09-08
CN1156492C (en) 2004-07-07
US6225284B1 (en) 2001-05-01
AU6515096A (en) 1997-01-30

Similar Documents

Publication Publication Date Title
DK0836427T3 (en) Satureringstang
DK1419802T3 (en) Gelindkapslingsstruktur
DK0850426T3 (en) Transpondearrangement
DK0835496T3 (en) Højfrekvensindentifikationsetiket
DK0747706T3 (en) Adduktbeskyttelsesassay
DK0865562T3 (en) Rørledningsforbindelsesdel
DK0811095T3 (en) Støttemursystem
DK0817797T3 (en) Glycopeptidantibiotikumderivater
DK0740002T3 (en) Polyolefinline
DK0747181T3 (en) Afgreningsordning
DK0874606T3 (en) Hofteledskålslegemeprotese
DK0721966T3 (en) Glansemulsionsmalinger
DK0757905T3 (en) Nasaldilatatorindretning
AT281132T (en) Spondylodeseimplantate
AT254432T (en) Wirbelsäulenhalterunsvorrichtung
AT490744T (en) Gewebsreparaturmatrix
AT240703T (en) Zwischenwirbelfusionierungseinrichtung
AT211131T (en) Arylsulfonylaminohydroxamsäurederivate
BR9609301A (en) Dialkyl-halogenophenyl-substituted ketoenois
AT198143T (en) Toothpases
AT385195T (en) Nadeless injectionsstelle
AT185214T (en) Displayboards
DK35196A (en) Rørsvulmeindstillingsmekanisme
AT346905T (en) Bleichkatalysatorteilchen
AT236322T (en) Schnellbauzelt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0835263

Country of ref document: EP